The MET Oncogene: An Update on Targeting Strategies DOI Creative Commons
Simona Gallo,

Consolata Beatrice Folco,

Tiziana Crepaldi

и другие.

Pharmaceuticals, Год журнала: 2024, Номер 17(11), С. 1473 - 1473

Опубликована: Ноя. 2, 2024

The MET receptor, commonly known as HGF (hepatocyte growth factor) is a focus of extensive scientific research. has been linked to embryonic development, tissue regeneration following injury, tumorigenesis, and cancer metastasis. These functions underscore its involvement in numerous cellular processes, including stemness, proliferation, motility, cell dissociation, survival. However, the enigmatic nature becomes apparent context cancer. When remains persistently activated, since gene undergoes genetic alterations, it initiates complex signaling cascade setting motion an aggressive metastatic program that characteristic malignant cells “invasive growth”. expanding knowledge opened up opportunities for therapeutic interventions, particularly realm oncology. Targeting presents promising strategy developing novel anti-cancer treatments. In this review, we provide updated overview drugs designed modulate signaling, highlighting kinase inhibitors, degraders, anti-MET/HGF monoclonal antibodies, MET-targeted antibody–drug conjugates. Through aim contribute ongoing advancement strategies targeting signaling.

Язык: Английский

The MET Oncogene: An Update on Targeting Strategies DOI Creative Commons
Simona Gallo,

Consolata Beatrice Folco,

Tiziana Crepaldi

и другие.

Pharmaceuticals, Год журнала: 2024, Номер 17(11), С. 1473 - 1473

Опубликована: Ноя. 2, 2024

The MET receptor, commonly known as HGF (hepatocyte growth factor) is a focus of extensive scientific research. has been linked to embryonic development, tissue regeneration following injury, tumorigenesis, and cancer metastasis. These functions underscore its involvement in numerous cellular processes, including stemness, proliferation, motility, cell dissociation, survival. However, the enigmatic nature becomes apparent context cancer. When remains persistently activated, since gene undergoes genetic alterations, it initiates complex signaling cascade setting motion an aggressive metastatic program that characteristic malignant cells “invasive growth”. expanding knowledge opened up opportunities for therapeutic interventions, particularly realm oncology. Targeting presents promising strategy developing novel anti-cancer treatments. In this review, we provide updated overview drugs designed modulate signaling, highlighting kinase inhibitors, degraders, anti-MET/HGF monoclonal antibodies, MET-targeted antibody–drug conjugates. Through aim contribute ongoing advancement strategies targeting signaling.

Язык: Английский

Процитировано

2